Improved thymic index, density and output in HIV-infected patients following low-dose growth hormone therapy: a placebo controlled study

Birgitte R Hansen; Lilian Kolte; Steen B Haugaard; Carsten Dirksen; Frank K Jensen; Lars P Ryder; Anna Louise Sørensen; Allan Flyvbjerg; Susanne D Nielsen; Ove Andersen; Birgitte R Hansen; Lilian Kolte; Steen B Haugaard; Carsten Dirksen; Frank K Jensen; Lars P Ryder; Anna Louise Sørensen; Allan Flyvbjerg; Susanne D Nielsen; Ove Andersen

doi:10.1097/QAD.0b013e3283303307

Improved thymic index, density and output in HIV-infected patients following low-dose growth hormone therapy: a placebo controlled study

Birgitte R Hansen, Lilian Kolte, Steen B Haugaard, Carsten Dirksen, Frank K Jensen, Lars P Ryder, Anna Louise Sørensen, Allan Flyvbjerg, Susanne D Nielsen, Ove Andersen, Birgitte R Hansen, Lilian Kolte, Steen B Haugaard, Carsten Dirksen, Frank K Jensen, Lars P Ryder, Anna Louise Sørensen, Allan Flyvbjerg, Susanne D Nielsen, Ove Andersen

Department of Clinical Medicine

21 Citations (Scopus)

Abstract

OBJECTIVES: To investigate the effect of low-dose, long-term recombinant human growth hormone (rhGH) therapy on immune reconstitution in human immunodeficiency virus (HIV)-infected patients with focus on thymic index, density and output. DESIGN: Randomized, placebo-controlled, double-blind, single-centre trial. METHODS: Forty-six HIV-infected Caucasian men on highly active antiretroviral therapy, 21-60 years of age, were included. Twenty-eight patients were randomized to 0.7 mg/day rhGH and 18 patients to placebo, administrated as daily subcutaneous injections between 1300 and 1500 h for 40 weeks. Endpoints were changes from baseline in thymic size and thymic output measured as T-cell receptor rearrangement excision circles (TREC) frequency and total TREC content, and total and naive CD4 cells. RESULTS: Thymic density and thymic index increased in the GH group, compared with the placebo group (28 versus 4 Hounsfield units, P = 0.006 and 1 versus 0, P = 0.004). TREC frequency and total TREC content increased in the GH group, compared with the placebo group (37 versus -8%, P = 0.049 and 51 versus -14%, P = 0.026). Total CD4 cells and naive CD4+ cells increased insignificantly more in the GH than the placebo group [11.4%, 95% confidence interval (CI) -6.0 to 28.9; P = 0.19 and 18%, interquartile range (IQR) -4, 40 versus 13%, IQR -12, 39; P = 0.79]. Therapy was well tolerated. CONCLUSIONS: Daily treatment with a low dose rhGH of 0.7 mg for 40 weeks stimulated thymopoiesis expressed by thymic index, density and area, TREC frequency and total TREC content in CD4 cells in HIV-infected patients on highly active antiretroviral therapy.

Original language	English
Journal	AIDS
Volume	23
Issue number	16
Pages (from-to)	2123-31
Number of pages	8
ISSN	0269-9370
DOIs	https://doi.org/10.1097/QAD.0b013e3283303307 https://doi.org/10.1097/QAD.0b013e3283303307
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

Cite this

Hansen, B. R., Kolte, L., Haugaard, S. B., Dirksen, C., Jensen, F. K., Ryder, L. P., Sørensen, A. L., Flyvbjerg, A., Nielsen, S. D., Andersen, O., Hansen, B. R., Kolte, L., Haugaard, S. B., Dirksen, C., Jensen, F. K., Ryder, L. P., Sørensen, A. L., Flyvbjerg, A., Nielsen, S. D., & Andersen, O. (2009). Improved thymic index, density and output in HIV-infected patients following low-dose growth hormone therapy: a placebo controlled study. AIDS, 23(16), 2123-31. https://doi.org/10.1097/QAD.0b013e3283303307, https://doi.org/10.1097/QAD.0b013e3283303307

Hansen, BR, Kolte, L, Haugaard, SB, Dirksen, C, Jensen, FK, Ryder, LP, Sørensen, AL, Flyvbjerg, A, Nielsen, SD, Andersen, O, Hansen, BR, Kolte, L, Haugaard, SB, Dirksen, C, Jensen, FK, Ryder, LP, Sørensen, AL, Flyvbjerg, A, Nielsen, SD & Andersen, O 2009, 'Improved thymic index, density and output in HIV-infected patients following low-dose growth hormone therapy: a placebo controlled study', AIDS, vol. 23, no. 16, pp. 2123-31. https://doi.org/10.1097/QAD.0b013e3283303307, https://doi.org/10.1097/QAD.0b013e3283303307

@article{97f17230aac011df928f000ea68e967b,

title = "Improved thymic index, density and output in HIV-infected patients following low-dose growth hormone therapy: a placebo controlled study",

abstract = "OBJECTIVES: To investigate the effect of low-dose, long-term recombinant human growth hormone (rhGH) therapy on immune reconstitution in human immunodeficiency virus (HIV)-infected patients with focus on thymic index, density and output. DESIGN: Randomized, placebo-controlled, double-blind, single-centre trial. METHODS: Forty-six HIV-infected Caucasian men on highly active antiretroviral therapy, 21-60 years of age, were included. Twenty-eight patients were randomized to 0.7 mg/day rhGH and 18 patients to placebo, administrated as daily subcutaneous injections between 1300 and 1500 h for 40 weeks. Endpoints were changes from baseline in thymic size and thymic output measured as T-cell receptor rearrangement excision circles (TREC) frequency and total TREC content, and total and naive CD4 cells. RESULTS: Thymic density and thymic index increased in the GH group, compared with the placebo group (28 versus 4 Hounsfield units, P = 0.006 and 1 versus 0, P = 0.004). TREC frequency and total TREC content increased in the GH group, compared with the placebo group (37 versus -8%, P = 0.049 and 51 versus -14%, P = 0.026). Total CD4 cells and naive CD4+ cells increased insignificantly more in the GH than the placebo group [11.4%, 95% confidence interval (CI) -6.0 to 28.9; P = 0.19 and 18%, interquartile range (IQR) -4, 40 versus 13%, IQR -12, 39; P = 0.79]. Therapy was well tolerated. CONCLUSIONS: Daily treatment with a low dose rhGH of 0.7 mg for 40 weeks stimulated thymopoiesis expressed by thymic index, density and area, TREC frequency and total TREC content in CD4 cells in HIV-infected patients on highly active antiretroviral therapy.",

author = "Hansen, {Birgitte R} and Lilian Kolte and Haugaard, {Steen B} and Carsten Dirksen and Jensen, {Frank K} and Ryder, {Lars P} and S{\o}rensen, {Anna Louise} and Allan Flyvbjerg and Nielsen, {Susanne D} and Ove Andersen and Hansen, {Birgitte R} and Lilian Kolte and Haugaard, {Steen B} and Carsten Dirksen and Jensen, {Frank K} and Ryder, {Lars P} and S{\o}rensen, {Anna Louise} and Allan Flyvbjerg and Nielsen, {Susanne D} and Ove Andersen",

year = "2009",

doi = "10.1097/QAD.0b013e3283303307",

language = "English",

volume = "23",

pages = "2123--31",

journal = "AIDS, Supplement",

issn = "1350-2840",

publisher = "Lippincott Williams & Wilkins",

number = "16",

}

TY - JOUR

T1 - Improved thymic index, density and output in HIV-infected patients following low-dose growth hormone therapy: a placebo controlled study

AU - Hansen, Birgitte R

AU - Kolte, Lilian

AU - Haugaard, Steen B

AU - Dirksen, Carsten

AU - Jensen, Frank K

AU - Ryder, Lars P

AU - Sørensen, Anna Louise

AU - Flyvbjerg, Allan

AU - Nielsen, Susanne D

AU - Andersen, Ove

AU - Hansen, Birgitte R

AU - Kolte, Lilian

AU - Haugaard, Steen B

AU - Dirksen, Carsten

AU - Jensen, Frank K

AU - Ryder, Lars P

AU - Sørensen, Anna Louise

AU - Flyvbjerg, Allan

AU - Nielsen, Susanne D

AU - Andersen, Ove

PY - 2009

Y1 - 2009

N2 - OBJECTIVES: To investigate the effect of low-dose, long-term recombinant human growth hormone (rhGH) therapy on immune reconstitution in human immunodeficiency virus (HIV)-infected patients with focus on thymic index, density and output. DESIGN: Randomized, placebo-controlled, double-blind, single-centre trial. METHODS: Forty-six HIV-infected Caucasian men on highly active antiretroviral therapy, 21-60 years of age, were included. Twenty-eight patients were randomized to 0.7 mg/day rhGH and 18 patients to placebo, administrated as daily subcutaneous injections between 1300 and 1500 h for 40 weeks. Endpoints were changes from baseline in thymic size and thymic output measured as T-cell receptor rearrangement excision circles (TREC) frequency and total TREC content, and total and naive CD4 cells. RESULTS: Thymic density and thymic index increased in the GH group, compared with the placebo group (28 versus 4 Hounsfield units, P = 0.006 and 1 versus 0, P = 0.004). TREC frequency and total TREC content increased in the GH group, compared with the placebo group (37 versus -8%, P = 0.049 and 51 versus -14%, P = 0.026). Total CD4 cells and naive CD4+ cells increased insignificantly more in the GH than the placebo group [11.4%, 95% confidence interval (CI) -6.0 to 28.9; P = 0.19 and 18%, interquartile range (IQR) -4, 40 versus 13%, IQR -12, 39; P = 0.79]. Therapy was well tolerated. CONCLUSIONS: Daily treatment with a low dose rhGH of 0.7 mg for 40 weeks stimulated thymopoiesis expressed by thymic index, density and area, TREC frequency and total TREC content in CD4 cells in HIV-infected patients on highly active antiretroviral therapy.

AB - OBJECTIVES: To investigate the effect of low-dose, long-term recombinant human growth hormone (rhGH) therapy on immune reconstitution in human immunodeficiency virus (HIV)-infected patients with focus on thymic index, density and output. DESIGN: Randomized, placebo-controlled, double-blind, single-centre trial. METHODS: Forty-six HIV-infected Caucasian men on highly active antiretroviral therapy, 21-60 years of age, were included. Twenty-eight patients were randomized to 0.7 mg/day rhGH and 18 patients to placebo, administrated as daily subcutaneous injections between 1300 and 1500 h for 40 weeks. Endpoints were changes from baseline in thymic size and thymic output measured as T-cell receptor rearrangement excision circles (TREC) frequency and total TREC content, and total and naive CD4 cells. RESULTS: Thymic density and thymic index increased in the GH group, compared with the placebo group (28 versus 4 Hounsfield units, P = 0.006 and 1 versus 0, P = 0.004). TREC frequency and total TREC content increased in the GH group, compared with the placebo group (37 versus -8%, P = 0.049 and 51 versus -14%, P = 0.026). Total CD4 cells and naive CD4+ cells increased insignificantly more in the GH than the placebo group [11.4%, 95% confidence interval (CI) -6.0 to 28.9; P = 0.19 and 18%, interquartile range (IQR) -4, 40 versus 13%, IQR -12, 39; P = 0.79]. Therapy was well tolerated. CONCLUSIONS: Daily treatment with a low dose rhGH of 0.7 mg for 40 weeks stimulated thymopoiesis expressed by thymic index, density and area, TREC frequency and total TREC content in CD4 cells in HIV-infected patients on highly active antiretroviral therapy.

U2 - 10.1097/QAD.0b013e3283303307

DO - 10.1097/QAD.0b013e3283303307

M3 - Journal article

C2 - 19625946

SN - 1350-2840

VL - 23

SP - 2123

EP - 2131

JO - AIDS, Supplement

JF - AIDS, Supplement

IS - 16

ER -

Improved thymic index, density and output in HIV-infected patients following low-dose growth hormone therapy: a placebo controlled study

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this